关注并星标CPHI制药在线2025年医药BD战场硝烟未散!上半年国内药企以超150笔交易掀起出海浪潮,近半数为License out,首付款金额、技术输出、新兴市场布局三大维度上演“神仙打架”。三生制药一剂双抗刷新行业天花板,和铂医药7连发技术平台震惊四座,复宏汉霖、百奥泰则用“借船出海”巧占全球市场。这场没有硝烟的战争,不仅彰显中国创新药的硬核实力,更暗藏未来十年国际化突围的关键密码。一、首付款...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.